Segall Bryant & Hamill LLC Takes $1.36 Million Position in Haemonetics Corporation (NYSE:HAE)

Segall Bryant & Hamill LLC purchased a new position in Haemonetics Corporation (NYSE:HAE - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,410 shares of the medical instruments supplier's stock, valued at approximately $1,361,000.

Other institutional investors have also recently made changes to their positions in the company. Rice Hall James & Associates LLC boosted its position in Haemonetics by 16.7% during the 1st quarter. Rice Hall James & Associates LLC now owns 54,083 shares of the medical instruments supplier's stock valued at $3,437,000 after buying an additional 7,740 shares during the period. Isthmus Partners LLC lifted its position in Haemonetics by 5.6% during the first quarter. Isthmus Partners LLC now owns 42,465 shares of the medical instruments supplier's stock valued at $2,699,000 after purchasing an additional 2,245 shares during the period. Louisiana State Employees Retirement System raised its position in Haemonetics by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier's stock worth $896,000 after acquiring an additional 200 shares during the period. Cerity Partners LLC raised its position in Haemonetics by 32.5% in the first quarter. Cerity Partners LLC now owns 11,058 shares of the medical instruments supplier's stock worth $703,000 after acquiring an additional 2,713 shares during the period. Finally, M&T Bank Corp bought a new position in Haemonetics in the first quarter worth approximately $243,000. Institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Barrington Research reissued an "outperform" rating and issued a $95.00 price objective on shares of Haemonetics in a research note on Friday, July 11th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Robert W. Baird initiated coverage on shares of Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective for the company. Wall Street Zen cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Citigroup upgraded shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target for the company in a report on Wednesday, July 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $97.30.

Haemonetics Stock Performance

Haemonetics stock traded up $0.72 during mid-day trading on Tuesday, reaching $74.49. 182,521 shares of the company traded hands, compared to its average volume of 678,932. The firm's fifty day moving average is $71.63 and its two-hundred day moving average is $67.79. The company has a market capitalization of $3.58 billion, a price-to-earnings ratio of 22.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.39. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. Haemonetics Corporation has a fifty-two week low of $55.30 and a fifty-two week high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The firm had revenue of $330.60 million for the quarter, compared to the consensus estimate of $329.38 million. During the same period in the prior year, the firm posted $0.90 earnings per share. The firm's quarterly revenue was down 3.5% compared to the same quarter last year. On average, equities research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.